Confo Therapeutics: High calibre chair
Drug discovery company Confo Therapeutics has appointed John Edward Berriman as non-executive director and chairman of the board of directors. Berriman is set to take his seat on the board December 21.
Berriman is already chairman of ReNeuron Group, Autifony Therapeutics and Depixus as well as non-executive director of Autolus. In the past, he has served as chairman of Heptares Therapeutics and Algeta and was a director of Micromet until its sale to Amgen. He was director of Abingworth Management, and before that, spent 14 years with Celltech Group.
Berriman has a degree in Chemical Engineering from the University of Cambridge and an MBA from the London Business School.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium